FIA
ELVN icon

FNY Investment Advisers’s Enliven Therapeutics ELVN Stock Holding History

FNY Investment Advisers’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126K Buy
+2,500
New +$106K 0.05% 291

Other funds holding ELVN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

FNY Investment Advisers's ELVN Position: Q2 2026 in Review

FNY Investment Advisers opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 2,500 shares worth $126K. The stake represents 0.05% of the portfolio and ranks #291 among its holdings.

9 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • FNY Investment Advisers held 2,500 shares of Enliven Therapeutics worth $126K as of Q2 2026.
  • Enliven Therapeutics was a new FNY Investment Advisers position in Q2 2026.
  • Enliven Therapeutics made up 0.05% of FNY Investment Advisers's portfolio in Q2 2026, its #291 holding.
  • 9 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.